<p>美国信托在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在礼来公司的股份增加了 147.1%。该基金在此期间额外购买了 3,644 股后，持有该公司 6,122 股股票。截至其最近的 SEC 文件，美国信托在礼来公司的持股价值为 4,772,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>黄金交叉提醒：3 只具有重大上涨潜力的股票</li>
</ul>
<p>其他大型投资者最近也调整了对该公司的持股。Evolution Wealth Management Inc.在第二季度购买了价值约 29,000 美元的礼来公司新股份。Lavaca Capital LLC 在第二季度将其在礼来公司的股份增加了 8.4%。Lavaca Capital LLC 现在拥有 1,303 股该公司的股票，价值 1,016,000 美元，此前在上个季度又购买了 101 股。中国泛海资产管理有限公司在第二季度将其在礼来公司的股份增加了 9.6%。中国泛海资产管理有限公司现在拥有 7,750 股该公司的股票，价值 6,041,000 美元，此前在上个季度又购买了 678 股。Orion Portfolio Solutions LLC 在第二季度将其在礼来公司的股份增加了 7.2%。Orion Portfolio Solutions LLC 现在拥有 50,823 股该公司的股票，价值 39,618,000 美元，此前在上个季度又购买了 3,399 股。最后，Munro Partners 在第二季度购买了价值约 98,872,000 美元的礼来公司新股份。对冲基金和其他机构投资者持有该公司 82.53% 的股票。</p>
<h2>礼来公司股价上涨 1.8%</h2>
<p>礼来公司（NYSE:LLY）周一开盘价为 1,027.68 美元。该股票的 50 日简单移动平均线为 939.47 美元，200 日简单移动平均线为 820.35 美元。该公司的市值为 9715.5 亿美元，市盈率为 50.28，PEG 比率为 1.14，贝塔值为 0.37。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,111.99 美元。该公司的债务股本比率为 1.71，速动比率为 1.24，流动比率为 1.55。</p>
<ul>
<li>2026 年将主导的三大投资主题</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日（星期四）发布了季度财报。该公司报告每股收益（EPS）为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。该公司在本季度的收入为 176 亿美元，而一致预期为 160.9 亿美元。去年同期，该公司每股收益为 1.18 美元。与去年同期相比，该公司的收入增长了 53.9%。礼来公司将其 2025 财年的指导目标设定为 23.000-23.700 EPS。分析师预计礼来公司今年的 EPS 将为 23.48。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 3 月 10 日（星期二）支付。记录在案的投资者将在 2 月 13 日（星期五）获得 1.73 美元的股息。该股息的除息日为 2 月 13 日（星期五）。这相当于年化 6.92 美元的股息，收益率为 0.7%。这比礼来公司之前的季度股息 1.50 美元有所增加。礼来公司的派息比率为 29.35%。</p>
<h2>分析师评级变动</h2>
<ul>
<li>5 只医疗保健股票值得关注，行业轮动已全面展开</li>
</ul>
<p>LLY 已成为多份分析师报告的主题。高盛集团将礼来公司的目标价格从 951.00 美元上调至 1,145.00 美元，并在 12 月 8 日（星期一）的研究报告中给予该公司 “买入” 评级。Leerink Partners 将礼来公司的评级从 “市场表现” 上调至 “跑赢大盘”，并在 11 月 10 日（星期一）的报告中将其目标价格从 886.00 美元上调至 1,104.00 美元。摩根大通将礼来公司的目标价格从 1,050.00 美元上调至 1,150.00 美元，并在 11 月 18 日（星期二）的研究报告中给予该公司 “增持” 评级。大和证券将礼来公司的评级从 “强烈买入” 下调至 “持有”，该报告于 8 月 17 日（星期日）发布。最后，National Bankshares 在 12 月 1 日（星期一）的研究报告中设定了礼来公司的目标价格为 1,286.00 美元。三位研究分析师对该股票给予 “强烈买入” 评级，十六位给予 “买入” 评级，六位给予 “持有” 评级。根据 MarketBeat，礼来公司目前的平均评级为 “适度买入”，平均目标价格为 1,121.90 美元。</p>
<p><strong>获取我们关于礼来公司的最新报告</strong></p>
<h2>关于礼来公司</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过礼来公司</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入状态</li>
<li>如何寻找被低估的股票</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>技术指标如何帮助你找到超卖股票</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>美国信托在第二季度将其在礼来的股份增加了 147.1%，目前持有 6,122 股，价值 477 万美元。礼来的股票开盘价为 1,027.68 美元，市值为 9,715.5 亿美元。该公司报告第三季度每股收益为 7.02 美元，超出预期，并宣布了分红增加。分析师们提高了目标价，高盛设定的目标价为 1,145.00 美元</p>

<p>American Trust raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 147.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,122 shares of the company's stock after acquiring an additional 3,644 shares during the period. American Trust's holdings in Eli Lilly and Company were worth $4,772,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>美国信托在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在礼来公司的股份增加了 147.1%。该基金在此期间额外购买了 3,644 股后，持有该公司 6,122 股股票。截至其最近的 SEC 文件，美国信托在礼来公司的持股价值为 4,772,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉提醒：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p>Other large investors have also recently modified their holdings of the company. Evolution Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at about $29,000. Lavaca Capital LLC lifted its stake in shares of Eli Lilly and Company by 8.4% in the second quarter. Lavaca Capital LLC now owns 1,303 shares of the company's stock worth $1,016,000 after buying an additional 101 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Eli Lilly and Company by 9.6% in the second quarter. China Universal Asset Management Co. Ltd. now owns 7,750 shares of the company's stock worth $6,041,000 after buying an additional 678 shares in the last quarter. Orion Porfolio Solutions LLC grew its holdings in shares of Eli Lilly and Company by 7.2% during the second quarter. Orion Porfolio Solutions LLC now owns 50,823 shares of the company's stock valued at $39,618,000 after buying an additional 3,399 shares during the last quarter. Finally, Munro Partners bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $98,872,000. Hedge funds and other institutional investors own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投资者最近也调整了对该公司的持股。Evolution Wealth Management Inc.在第二季度购买了价值约 29,000 美元的礼来公司新股份。Lavaca Capital LLC 在第二季度将其在礼来公司的股份增加了 8.4%。Lavaca Capital LLC 现在拥有 1,303 股该公司的股票，价值 1,016,000 美元，此前在上个季度又购买了 101 股。中国泛海资产管理有限公司在第二季度将其在礼来公司的股份增加了 9.6%。中国泛海资产管理有限公司现在拥有 7,750 股该公司的股票，价值 6,041,000 美元，此前在上个季度又购买了 678 股。Orion Portfolio Solutions LLC 在第二季度将其在礼来公司的股份增加了 7.2%。Orion Portfolio Solutions LLC 现在拥有 50,823 股该公司的股票，价值 39,618,000 美元，此前在上个季度又购买了 3,399 股。最后，Munro Partners 在第二季度购买了价值约 98,872,000 美元的礼来公司新股份。对冲基金和其他机构投资者持有该公司 82.53% 的股票。</p>
</div><h2>Eli Lilly and Company Trading Up 1.8%</h2>
<div class="lb-trans"><h2>礼来公司股价上涨 1.8%</h2>
</div><p>Shares of NYSE:LLY opened at $1,027.68 on Monday. The stock's 50-day simple moving average is $939.47 and its two-hundred day simple moving average is $820.35. The stock has a market capitalization of $971.55 billion, a price-to-earnings ratio of 50.28, a PEG ratio of 1.14 and a beta of 0.37. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY）周一开盘价为 1,027.68 美元。该股票的 50 日简单移动平均线为 939.47 美元，200 日简单移动平均线为 820.35 美元。该公司的市值为 9715.5 亿美元，市盈率为 50.28，PEG 比率为 1.14，贝塔值为 0.37。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,111.99 美元。该公司的债务股本比率为 1.71，速动比率为 1.24，流动比率为 1.55。</p>
</div><ul>
<li>The Top 3 Investment Themes That Will Dominate 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>2026 年将主导的三大投资主题</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the firm posted $1.18 earnings per share. The firm's revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日（星期四）发布了季度财报。该公司报告每股收益（EPS）为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。该公司在本季度的收入为 176 亿美元，而一致预期为 160.9 亿美元。去年同期，该公司每股收益为 1.18 美元。与去年同期相比，该公司的收入增长了 53.9%。礼来公司将其 2025 财年的指导目标设定为 23.000-23.700 EPS。分析师预计礼来公司今年的 EPS 将为 23.48。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's payout ratio is 29.35%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 3 月 10 日（星期二）支付。记录在案的投资者将在 2 月 13 日（星期五）获得 1.73 美元的股息。该股息的除息日为 2 月 13 日（星期五）。这相当于年化 6.92 美元的股息，收益率为 0.7%。这比礼来公司之前的季度股息 1.50 美元有所增加。礼来公司的派息比率为 29.35%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗保健股票值得关注，行业轮动已全面展开</li>
</ul>
</div><p>LLY has been the topic of several analyst reports. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, December 8th. Leerink Partners raised Eli Lilly and Company from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and upped their price target for the company from $886.00 to $1,104.00 in a report on Monday, November 10th. JPMorgan Chase &amp; Co. increased their price objective on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, November 18th. Daiwa America lowered Eli Lilly and Company from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, August 17th. Finally, National Bankshares set a $1,286.00 target price on shares of Eli Lilly and Company in a research note on Monday, December 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $1,121.90.</p>
<div class="lb-trans"><p>LLY 已成为多份分析师报告的主题。高盛集团将礼来公司的目标价格从 951.00 美元上调至 1,145.00 美元，并在 12 月 8 日（星期一）的研究报告中给予该公司 “买入” 评级。Leerink Partners 将礼来公司的评级从 “市场表现” 上调至 “跑赢大盘”，并在 11 月 10 日（星期一）的报告中将其目标价格从 886.00 美元上调至 1,104.00 美元。摩根大通将礼来公司的目标价格从 1,050.00 美元上调至 1,150.00 美元，并在 11 月 18 日（星期二）的研究报告中给予该公司 “增持” 评级。大和证券将礼来公司的评级从 “强烈买入” 下调至 “持有”，该报告于 8 月 17 日（星期日）发布。最后，National Bankshares 在 12 月 1 日（星期一）的研究报告中设定了礼来公司的目标价格为 1,286.00 美元。三位研究分析师对该股票给予 “强烈买入” 评级，十六位给予 “买入” 评级，六位给予 “持有” 评级。根据 MarketBeat，礼来公司目前的平均评级为 “适度买入”，平均目标价格为 1,121.90 美元。</p>
</div><p><strong>Get Our Latest Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>获取我们关于礼来公司的最新报告</strong></p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于礼来公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>ETF Screener: Uses and Step-by-Step Guide</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>How to Find Undervalued Stocks</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过礼来公司</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入状态</li>
<li>如何寻找被低估的股票</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>技术指标如何帮助你找到超卖股票</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

美国信托购入了礼来公司 3,644 股股票 $LLY